Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immunocore Holdings (IMCR)
NASDAQ:IMCR
Holding IMCR?
Track your performance easily
IMCR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$27.69 - $76.98
Previous Close$28.33
Volume283.34K
Average Volume (3M)266.46K
Market Cap
$1.42B
Enterprise Value$1.06B
Total Cash (Recent Filing)$442.63M
Total Debt (Recent Filing)$84.03M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Feb 26, 2025EPS Estimate
-$0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.96
Shares Outstanding48,088,346
10 Day Avg. Volume317,784
30 Day Avg. Volume266,460
Standard Deviation0.15
R-Squared0.05
Alpha-0.00549
Financial Highlights & Ratios
Price to Book (P/B)3.79
Price to Sales (P/S)9.37
Price to Cash Flow (P/CF)36.20
P/FCF Ratio26.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.40
Enterprise Value/Gross Profit4.28
Enterprise Value/Ebitda-33.52
Forecast
1Y Price Target
$62.15Price Target Upside119.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
Immunocore Holdings News
PremiumCompany Announcements
Immunocore Holdings Prepares Early Loan Agreement Termination
PremiumCompany Announcements
Immunocore Holdings Plc Reports Strong Q3 Revenue Growth
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentPromising clinical evidence suggests that brenetafusp is clinically active as monotherapy and may enhance the effectiveness of chemotherapy in heavily pre-treated ovarian cancer patients.
Financial PositionSubstantial cash reserves of $901.3M are expected to be sufficient to fund operations for over 36 months.
Product LaunchThe launch of KIMMTRAK for metastatic uveal melanoma is progressing well with revenues exceeding consensus expectations.
Bears Say
Clinical Development ChallengesBrenetafusp trials are being done in heavily pretreated patients, which makes achieving a high response rate challenging.
Financial OutlookPrice target is lowered to $71 due to increased development risk for brene in NSCLC.
Investor SentimentImmunocore did remove the potential announcement of NSCLC from their PRAME program due to limited investor enthusiasm for this early readout.
---
Ownership Overview
― Insiders
31.38% Mutual Funds
47.11% Other Institutional Investors
20.48% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMCR FAQ
What was Immunocore Holdings’s price range in the past 12 months?
Immunocore Holdings lowest stock price was $27.69 and its highest was $76.98 in the past 12 months.
What is Immunocore Holdings’s market cap?
Currently, no data Available
When is Immunocore Holdings’s upcoming earnings report date?
Immunocore Holdings’s upcoming earnings report date is Feb 26, 2025 which is in 66 days.
How were Immunocore Holdings’s earnings last quarter?
Immunocore Holdings released its earnings results on Nov 06, 2024. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of -$0.343 by $0.513.
Is Immunocore Holdings overvalued?
According to Wall Street analysts Immunocore Holdings’s price is currently Undervalued.
Does Immunocore Holdings pay dividends?
Immunocore Holdings does not currently pay dividends.
What is Immunocore Holdings’s EPS estimate?
Immunocore Holdings’s EPS estimate is -$0.23.
How many shares outstanding does Immunocore Holdings have?
Immunocore Holdings has 50,032,770 shares outstanding.
What happened to Immunocore Holdings’s price movement after its last earnings report?
Immunocore Holdings reported an EPS of $0.17 in its last earnings report, beating expectations of -$0.343. Following the earnings report the stock price went up 1.576%.
Which hedge fund is a major shareholder of Immunocore Holdings?
Among the largest hedge funds holding Immunocore Holdings’s share is PRIMECAP Management Co. It holds Immunocore Holdings’s shares valued at 77M.
---
Immunocore Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$62.15 (119.42% Upside)
$62.15 (119.42% Upside)
Blogger Sentiment
Bullish
IMCR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 526.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 9.0%
Last 30 Days ▲ 9.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.40%
12-Months-Change
Fundamentals
Return on Equity
-12.85%
Trailing 12-Months
Asset Growth
91.47%
Trailing 12-Months
Company Description
Immunocore Holdings
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases.
---
IMCR Company Deck
---
IMCR Earnings Call
Q2 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong performance and growth in the U.S. market for KIMMTRAK, along with significant advancements in the clinical pipeline. However, challenges in the European market due to reimbursement issues and a stable net loss were noted as concerns.Read More>---
IMCR Stock 12 Month Forecast
Average Price Target
$62.15
▲(119.42% Upside)
Technical Analysis
Ionis Pharmaceuticals
―
Fate Therapeutics
―
Revolution Medicines
―
Blueprint Medicines
―
Best Analysts Covering IMCR
1 Year
1 Year Success Rate
5/11 ratings generated profit
1 Year Average Return
+5.89%
reiterated a buy rating last month
Copying Jessica Fye's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +5.89% per trade.
---